Faculty profile
Natasha Chandok
Back to faculty122 publications.
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
Levy C, Abouda GF, Bilir BM, Bonder A, Bowlus CL, Campos-Varela I, Cazzagon N, Chandok N, Cheent K, Cortez-Pinto H
Five public health measures to improve the liver health of Canadians.
Chandok N, Yoshida EM
Use of maralixibat for the treatment of cholestatic pruritus in late-onset PFIC
Bernstein D, Tiev M, Crippin J, Rodas F, Adeyemi A, Chandok N, Mayo. MJ
Canadian hepatology needs a strong, united Canada
Yoshida EM, Bain VG, Coffin CS, Congly SE, Lee SS, Montano-Loza AJ, Sebastiani G, Chandok N
Maralixibat for PFIC.
Chandok N, Yoshida EM
LONG-TERM DATA OF ELAFIBRANOR IN PRIMARY SCLEROSING CHOLANGITIS: INTERIM SAFETY AND EFFICACY DATA FROM THE ONGOING OPEN-LABEL EXTENSION OF THE ELMWOOD PHASE II TRIAL
Bowlus CL, Levy C, Abouda GF, Bilir BM, Campos-Varela I, Cazzagon N, Chandok N, Cheent K, Cortez-Pinto H, Demir M
The emerging role of liver transplantation in metastatic colorectal cancer
Rafael V, Yoshida EM, Chandok N
PPAR agonists: the next innovation in hepatology
Chandok N, Yoshida EM
A hepatology hero rides off into the sunset: A tribute to Dr Gerald Minuk
Yoshida EM, Kaita K, Chandok N
Elafibranor for primary sclerosing cholangitis: the ELMWOOD phase II randomised controlled trial
Levy C, Abouda G, Bilir B, Bonder A, Bowlus CL, Campos-Varela I, Cazzagon N, Chandok N, Cheent K, Cortez-Pinto H
Frequent collaborators
6A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.